Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.
To TM, Exuzides A, Abbass IM, Patel AM, Ta JT, Surinach A, Fuller RLM, Luo J.
To TM, et al. Among authors: surinach a.
J Manag Care Spec Pharm. 2022 Nov;28(11):1228-1239. doi: 10.18553/jmcp.2022.28.11.1228.
J Manag Care Spec Pharm. 2022.
PMID: 36282937
Free PMC article.
OBJECTIVE: To quantify HCRU and costs for people with HD, overall and by disease stage, and compare these with non-HD controls. METHODS: This was a retrospective cohort study using administrative claims data from the IBM MarketScan Commercial, Multi-State Medicaid, and Med …
OBJECTIVE: To quantify HCRU and costs for people with HD, overall and by disease stage, and compare these with non-HD controls. METHODS: Thi …